

Neil J Stone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5711181/publications.pdf>

Version: 2024-02-01

222
papers

40,175
citations

36303

51
h-index

2895

190
g-index

229
all docs

229
docs citations

229
times ranked

33677
citing authors

#	ARTICLE	IF	CITATIONS
1	Eruptive Xanthomas: Importance of Recognition to Reduce Delay of Effective Triglyceride Reduction. <i>American Journal of Medicine</i> , 2022, 135, 444-447.	1.5	6
2	Treating Severe Hypercholesterolemiaâ€”If Not Now, When?. <i>JAMA Cardiology</i> , 2022, 7, 128.	6.1	4
3	Managing Atherosclerotic Cardiovascular Risk in Young Adults. <i>Journal of the American College of Cardiology</i> , 2022, 79, 819-836.	2.8	72
4	Association between statin use and cognitive function: A systematic review of randomized clinical trials and observational studies. <i>Journal of Clinical Lipidology</i> , 2021, 15, 22-32.e12.	1.5	19
5	The Telehealth Ten: A Guide for a Patient-Assisted Virtual Physical Examination. <i>American Journal of Medicine</i> , 2021, 134, 48-51.	1.5	90
6	How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol. <i>European Heart Journal</i> , 2021, 42, 2154-2169.	2.2	28
7	Facility-Level Variation in Reported Statin-Associated Side Effects Among Patients with Atherosclerotic Cardiovascular Diseaseâ€”Perspective from the Veterans Affairs Healthcare System. <i>Cardiovascular Drugs and Therapy</i> , 2021, , 1.	2.6	6
8	Tracking Residual Risk. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1451-1453.	2.8	3
9	Cost-effectiveness of Statin Use Guidelines. <i>JAMA Cardiology</i> , 2021, 6, 363.	6.1	0
10	A possible mechanism of hyperlipidemia in a patient with metastatic non-small cell lung cancer on lorlatinib therapy. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 2010-2013.	0.9	9
11	Update on the omega-3 fatty acid trial landscape: A narrative review with implications for primary prevention. <i>Journal of Clinical Lipidology</i> , 2021, 15, 545-555.	1.5	7
12	Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context. <i>Progress in Cardiovascular Diseases</i> , 2021, 68, 2-6.	3.1	9
13	Optimizing the Potential for Telehealth in Cardiovascular Care (in the Era of COVID-19): Time Will Tell. <i>American Journal of Medicine</i> , 2021, 134, 945-951.	1.5	16
14	2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia. <i>Journal of the American College of Cardiology</i> , 2021, 78, 960-993.	2.8	146
15	Coronary Artery Calcium: Where Do We Stand After Over 3 Decades?. <i>American Journal of Medicine</i> , 2021, 134, 1091-1095.	1.5	3
16	Necessity of Coronary CT Scans. <i>JAMA Internal Medicine</i> , 2021, 181, 1258.	5.1	1
17	A â€”Rule of Thumbâ€”™ Aids Evaluation of Severe Hypercholesterolemia to Recognize Familial Hypercholesterolemia. <i>American Journal of Medicine</i> , 2021, 134, e510-e511.	1.5	0
18	High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2660-2670.	3.0	7

#	ARTICLE	IF	CITATIONS
19	Coronary artery calcium scoring in patients with statin associated muscle symptoms: Prescribing statins for those most likely to benefit. <i>Journal of Clinical Lipidology</i> , 2021, , .	1.5	2
20	Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system. <i>Journal of Clinical Lipidology</i> , 2021, 15, 832-839.	1.5	4
21	The 2018 AHA/ACC/Multisociety Cholesterol Guidelines: A Personalized Approach to Risk Reduction. <i>Contemporary Cardiology</i> , 2021, , 179-200.	0.1	0
22	Comparison of 2018 AHA-ACC Multi-Society Cholesterol Guidelines with 2013 ACC-AHA Cholesterol Guidelines. <i>Contemporary Cardiology</i> , 2021, , 107-120.	0.1	0
23	Cardiology clinic visit increases likelihood of evidence-based cholesterol prescribing in severe hypercholesterolemia. <i>Clinical Cardiology</i> , 2021, 44, 186-192.	1.8	4
24	Shared decision making and patient reported outcomes among adults with atherosclerotic cardiovascular disease, medical expenditure panel survey 2006-2015. <i>American Journal of Preventive Cardiology</i> , 2021, 8, 100281.	3.0	6
25	Editorial commentary: Risk factors, enhancing factors and ASCVD in inflammatory bowel diseases. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 470-471.	4.9	0
26	Nondietary Cardiovascular Health Metrics With Patient Experience and Loss of Productivity Among US Adults Without Cardiovascular Disease: The Medical Expenditure Panel Survey 2006 to 2015. <i>Journal of the American Heart Association</i> , 2020, 9, e016744.	3.7	15
27	The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol in Diabetes. <i>Diabetes Care</i> , 2020, 43, 1673-1678.	8.6	31
28	The Role of Sex-Specific Risk Factors in the Risk Assessment of Atherosclerotic Cardiovascular Disease for Primary Prevention in Women. <i>Current Atherosclerosis Reports</i> , 2020, 22, 46.	4.8	14
29	Rapid Diet Assessment Screening Tools for Cardiovascular Disease Risk Reduction Across Healthcare Settings: A Scientific Statement From the American Heart Association. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e000094.	2.2	60
30	Risk Differences in Secondary Prevention Patients Who Present With Acute Coronary Syndrome and Implications of Guideline-Directed Cholesterol Management. <i>American Journal of Cardiology</i> , 2020, 133, 1-6.	1.6	0
31	Worth Remembering: Cardiac Memory Presenting as Deep Anterior T-Wave Inversions Explained by Intermittent Left Bundle Branch Block. <i>American Journal of Cardiology</i> , 2020, 135, 174-176.	1.6	1
32	Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statin-associated Side Effects. <i>Journal of the American Heart Association</i> , 2020, 9, e017915.	3.7	14
33	Same evidence, varying viewpoints: Three questions illustrating important differences between United States and European cholesterol guideline recommendations. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100117.	3.0	2
34	Perspective: Childhood Obesity Requires New Strategies for Prevention. <i>Advances in Nutrition</i> , 2020, 11, 1071-1078.	6.4	38
35	A Meta-Analysis Assessing Additional LDL-C Reduction from Addition of a Bile Acid Sequestrant to Statin Therapy. <i>American Journal of Medicine</i> , 2020, 133, 1322-1327.	1.5	16
36	Comparing Primary Prevention Recommendations. <i>Circulation</i> , 2020, 141, 1117-1120.	1.6	16

#	ARTICLE	IF	CITATIONS
37	Primary Prevention Statins in Older Adults: Personalized Care for a Heterogeneous Population. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 467-473.	2.6	6
38	Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.8	14
39	Secondary Prevention for Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2020, 141, 1121-1123.	1.6	56
40	Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C \geq 100 mg/dl. <i>PLoS ONE</i> , 2020, 15, e0240166.	2.5	2
41	Title is missing!. , 2020, 15, e0240166.		0
42	Title is missing!. , 2020, 15, e0240166.		0
43	Title is missing!. , 2020, 15, e0240166.		0
44	Title is missing!. , 2020, 15, e0240166.		0
45	Lipids and Women's Health: Recent Updates and Implications for Practice. <i>Journal of Women's Health</i> , 2019, 28, 752-760.	3.3	4
46	A Clinician's Guide to Healthy Eating for Cardiovascular Disease Prevention. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2019, 3, 251-267.	2.4	72
47	Advanced Lipid Thinking Prior to Incorporating Advanced Lipid Testing. <i>American Journal of Medicine</i> , 2019, 132, 1279-1284.	1.5	0
48	Treating Hypercholesterolemia in Older Adults. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 695.	7.4	1
49	Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines. <i>Journal of the American College of Cardiology</i> , 2019, 74, 712-714.	2.8	21
50	Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons. <i>American Heart Journal</i> , 2019, 209, 79-87.	2.7	19
51	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 1. <i>American Journal of Medicine</i> , 2019, 132, e569-e580.	1.5	18
52	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 2. <i>American Journal of Medicine</i> , 2019, 132, e599-e609.	1.5	10
53	Elevated apolipoprotein B as a risk-enhancing factor in 2018 cholesterol guidelines. <i>Journal of Clinical Lipidology</i> , 2019, 13, 356-359.	1.5	8
54	JCL roundtable. The 2018 AHA/ACC/Multisociety Cholesterol Guidelines: Process and product. <i>Journal of Clinical Lipidology</i> , 2019, 13, 345-355.	1.5	0

#	ARTICLE	IF	CITATIONS
55	Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System. American Journal of Medicine, 2019, 132, e693-e700.	1.5	16
56	2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol—Secondary Prevention. JAMA Cardiology, 2019, 4, 589.	6.1	38
57	Four Cases of Cholesterol Management Informed by the 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol. JAMA Cardiology, 2019, 4, 473.	6.1	1
58	2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol. JAMA Cardiology, 2019, 4, 488.	6.1	33
59	2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline*. Annals of Internal Medicine, 2019, 170, 779.	3.9	38
60	The 2018 AHA/ACC/Multi-Society Cholesterol guidelines: Looking at past, present and future. Progress in Cardiovascular Diseases, 2019, 62, 375-383.	3.1	32
61	Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation, 2019, 139, 410-412.	1.6	12
62	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology, 2019, 73, e285-e350.	2.8	1,550
63	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 139, e1046-e1081.	1.6	361
64	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 139, e1082-e1143.	1.6	2,380
65	Treatment Gap in Primary Prevention Patients Presenting With Acute Coronary Syndrome. American Journal of Cardiology, 2019, 123, 368-374.	1.6	5
66	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary. Journal of the American College of Cardiology, 2019, 73, 3168-3209.	2.8	1,128
67	Sudden Creatine Kinase Elevation When an Athlete Starts Boxing: Looking Deeper Prior to Knocking the Statin Out. American Journal of Medicine, 2018, 131, e333-e334.	1.5	1
68	A Comparative Analysis of Current Lipid Treatment Guidelines. Journal of the American College of Cardiology, 2018, 71, 794-799.	2.8	20
69	A New HOPE? Lessons from Heart Outcomes Prevention Evaluation-3. American Journal of Medicine, 2018, 131, 134-140.	1.5	1
70	Statins for Primary Prevention in Older Adults—Moving Toward Evidence-Based Decision Making. Journal of the American Geriatrics Society, 2018, 66, 2188-2196.	2.6	50
71	Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥ 190 mg/dL. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004652.	2.2	43
72	Measuring Low-Density Lipoprotein Cholesterol. JAMA Cardiology, 2018, 3, 754.	6.1	0

#	ARTICLE	IF	CITATIONS
73	Potential for Net Benefit Should Guide Preventive Therapy. <i>Circulation</i> , 2017, 135, 630-632.	1.6	2
74	Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association. <i>Circulation</i> , 2017, 136, e1-e23.	1.6	884
75	Statins in Secondary Prevention. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2707-2709.	2.8	7
76	Use of Statins in Adults Older Than 75 Years. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1081.	7.4	0
77	Factors Affecting the Cost of Airplanes and Use of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors. <i>JAMA Cardiology</i> , 2017, 2, 596.	6.1	5
78	Relation of Intensity of Statin Therapy and Outcomes After Transcatheter Aortic Valve Replacement. <i>American Journal of Cardiology</i> , 2017, 119, 1832-1838.	1.6	24
79	Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies. <i>World Journal of Cardiology</i> , 2016, 8, 201.	1.5	47
80	Advances in Lipid Testing: A Practical Step Forward. <i>Clinical Chemistry</i> , 2016, 62, 905-906.	3.2	5
81	Looking Beyond Statins. <i>Circulation</i> , 2016, 134, 1944-1947.	1.6	1
82	Metabolic Profilesâ€”Based on the 2013 Prevention Guidelines. , 2016, , 83-88.		0
83	The Pooled Cohort Equations for Predicting Risk of Myocardial Infarction and Stroke: Validated in Representative Natural History Populations. <i>Mayo Clinic Proceedings</i> , 2016, 91, 692-694.	3.0	3
84	MY APPROACH to cardiovascular risk assessment to reduce atherosclerotic risk. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 92-93.	4.9	1
85	Shared Decision-Making and Patient Empowerment in Preventive Cardiology. <i>Current Cardiology Reports</i> , 2016, 18, 49.	2.9	89
86	Patients and Physicians Beliefs and Practices Regarding Adherence to Cardiovascular Medication. <i>JAMA Cardiology</i> , 2016, 1, 470.	6.1	24
87	Reply. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1710-1711.	2.8	0
88	Refining Statin Prescribing in Lower-Risk Individuals. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1690-1697.	2.8	19
89	Metabolic Syndrome: An Evolving Clinical Construct. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 172-177.	3.1	24
90	Statin Use and Aneurysm Risk in Patients With Bicuspid Aortic Valve Disease. <i>Clinical Cardiology</i> , 2016, 39, 41-47.	1.8	22

#	ARTICLE	IF	CITATIONS
91	Author's Reply. <i>Clinical Cardiology</i> , 2016, 39, 307-307.	1.8	0
92	Preventing Atherosclerotic Cardiovascular Disease Using American College of Cardiology and American Heart Association Prevention Guidelines: Some Good News, But Caveats Remain. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	5
93	New Eyes on Lipids and Lipoproteins. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 95-96.	3.1	3
94	What to say and how to say it. <i>Current Opinion in Cardiology</i> , 2016, 31, 537-544.	1.8	28
95	The ABCDs of Lifestyle Counseling. <i>JAMA Cardiology</i> , 2016, 1, 505.	6.1	16
96	The ASCVD Risk Estimator App. <i>Journal of the American College of Cardiology</i> , 2016, 67, 350-352.	2.8	22
97	Nonfasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come?. <i>Clinical Chemistry</i> , 2016, 62, 428-435.	3.2	22
98	Statin therapy across the lifespan: evidence in major age groups. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 341-366.	1.5	12
99	New Strategies to Treat High Cholesterol. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1169.	7.4	0
100	Getting What the Guidelines Stated Matters. <i>Journal of the American College of Cardiology</i> , 2016, 67, 119-120.	2.8	0
101	Fasting or Nonfasting Lipid Measurements. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1227-1234.	2.8	63
102	Treatment of Blood Cholesterol to Reduce Risk for Atherosclerotic Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2016, 164, 135.	3.9	4
103	The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. <i>European Heart Journal</i> , 2015, 36, 2110-2118.	2.2	55
104	Statins and Nonadherence. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2015, 20, 447-456.	2.0	14
105	Lowering LDL Cholesterol Is Good, but How and in Whom?. <i>New England Journal of Medicine</i> , 2015, 372, 1564-1565.	27.0	17
106	Primary Risk Prevention in the Elderly: Use Clinician-Patient Discussions, Not Automatic Statin Prescribing. <i>American Journal of Medicine</i> , 2015, 128, 804-806.	1.5	3
107	Cholesterol Guidelines Do Not Endorse "One Size Fits All". <i>Journal of the American College of Cardiology</i> , 2015, 65, 1640-1643.	2.8	1
108	COCATS 4 Task Force 2: Training in Preventive Cardiovascular Medicine. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1754-1762.	2.8	17

#	ARTICLE	IF	CITATIONS
109	ACC 2015 Core Cardiovascular Training Statement (COCATS 4) (Revision of COCATS 3). Journal of the American College of Cardiology, 2015, 65, 1721-1723.	2.8	67
110	Familial Hypercholesterolemia and the 2013 American College of Cardiology/American Heart Association Guidelines: Myths, Oversimplification, and Misinterpretation Versus Facts. American Journal of Cardiology, 2015, 116, 481-484.	1.6	16
111	Getting Guidelines Correct. Journal of the American College of Cardiology, 2015, 65, 2051-2052.	2.8	2
112	Clinician-Patient Risk Discussion for Atherosclerotic Cardiovascular Disease Prevention. Journal of the American College of Cardiology, 2015, 65, 1361-1368.	2.8	142
113	A Systematic Review of the Usefulness of Statin Therapy in HIV-Infected Patients. American Journal of Cardiology, 2015, 115, 1760-1766.	1.6	80
114	Letter by Stone et al Regarding Article, "Perspective on the 2013 American Heart Association/American College of Cardiology Guideline for the Use of Statins in Primary Prevention of Low-Risk Individuals". Circulation Research, 2014, 115, e1-2.	4.5	2
115	Coronary Heart Disease Risks Associated with High Levels of HDL Cholesterol. Journal of the American Heart Association, 2014, 3, e000519.	3.7	99
116	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention. Journal of the American Heart Association, 2014, 3, e001098.	3.7	24
117	Statins in Very Elderly Adults (Debate). Journal of the American Geriatrics Society, 2014, 62, 943-945.	2.6	30
118	Guidelines for Cardiovascular Risk Assessment and Cholesterol Treatment. JAMA - Journal of the American Medical Association, 2014, 311, 2235.	7.4	7
119	Statins, risk assessment, and the new American prevention guidelines. Lancet, The, 2014, 383, 600-602.	13.7	50
120	Addressing Statin Adverse Effects in the Clinic. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 533-542.	2.0	22
121	2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Journal of the American College of Cardiology, 2014, 63, 2889-2934.	2.8	3,414
122	2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation, 2014, 129, S49-73.	1.6	2,823
123	Lifestyle Modification for Metabolic Syndrome: A Systematic Review. American Journal of Medicine, 2014, 127, 1242.e1-1242.e10.	1.5	131
124	2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation, 2014, 129, S1-45.	1.6	4,842
125	2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Journal of the American College of Cardiology, 2014, 63, 2935-2959.	2.8	3,277
126	Reply. Journal of Vascular Surgery, 2014, 59, 876.	1.1	3

#	ARTICLE	IF	CITATIONS
127	Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: Synopsis of the 2013 American College of Cardiology/American Heart Association Cholesterol Guideline. <i>Annals of Internal Medicine</i> , 2014, 160, 339-343.	3.9	164
128	Understanding the new atherosclerotic cardiovascular disease prevention guidelines: going beyond the headlines. <i>Clinical Lipidology</i> , 2014, 9, 121-123.	0.4	0
129	Statin use and lower extremity amputation risk in nonelderly diabetic patients. <i>Journal of Vascular Surgery</i> , 2013, 58, 1578-1585.e1.	1.1	42
130	Look Before You Leap (Treat): Severely Low High-density Lipoprotein Cholesterol. <i>American Journal of Medicine</i> , 2013, 126, e1-e2.	1.5	0
131	Drugs for Elevated Low-Density Lipoprotein Cholesterol. , 2013, , 421-433.		0
132	Reducing Residual Risk in Secondary Prevention of Cardiovascular Disease. <i>Circulation</i> , 2012, 125, 1958-1960.	1.6	16
133	Emphasizing Statin Safety in the Hospitalized Patient: A Review. <i>American Journal of Medicine</i> , 2012, 125, 845-853.	1.5	20
134	Obesity Paradox in Amputation Risk Among Nonelderly Diabetic Men. <i>Obesity</i> , 2012, 20, 460-462.	3.0	25
135	Severe hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2012, 6, 397-408.	1.5	15
136	Relation of Body Mass Index to Late Survival After Valvular Heart Surgery. <i>American Journal of Cardiology</i> , 2012, 110, 1667-1678.	1.6	39
137	Management of severe hypertriglyceridemia in the hospital: A review. <i>Journal of Hospital Medicine</i> , 2012, 7, 431-438.	1.4	17
138	Midterm Benefits of Preoperative Statin Therapy in Patients Undergoing Isolated Valve Surgery. <i>Annals of Thoracic Surgery</i> , 2012, 93, 1881-1887.	1.3	9
139	Triglycerides and Cardiovascular Disease. <i>Circulation</i> , 2011, 123, 2292-2333.	1.6	1,511
140	Should the Routine Physical Examination Include Squat Maneuvers?. <i>American Journal of Medicine</i> , 2011, 124, 702-704.	1.5	3
141	Clinical Status and Cardiovascular Risk Profile of Adults with a History of Juvenile Dermatomyositis. <i>Journal of Pediatrics</i> , 2011, 159, 795-801.	1.8	55
142	Healthy Lifestyle Behaviors and Triglycerides. <i>Lippincott S Bone and Joint Newsletter</i> , 2011, 37, 1-5.	0.0	2
143	Strategies for Treating Abnormal Lipid Profiles with Drugs. , 2011, , 163-193.		1
144	Effect of Amiodarone-Induced Hyperthyroidism on Left Ventricular Outflow Obstruction After Septal Myectomy for Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2010, 106, 1670-1672.	1.6	1

#	ARTICLE	IF	CITATIONS
145	Perioperative statin therapy reduces mortality in normolipidemic patients undergoing cardiac surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2010, 140, 1018-1027.	0.8	23
146	The 75-Year-Old Patient with Hypercholesterolemia: To Treat or Not to Treat?. <i>Nutrition Reviews</i> , 2009, 52, 31-33.	5.8	2
147	Clinical Evaluation for Genetic and Secondary Causes of Dyslipidemia. , 2009, , 144-157.		0
148	Dietary Patterns for the Prevention and Treatment of Cardiovascular Disease. , 2009, , 217-231.		0
149	Practical management of patients with hypertension and metabolic risk factors: Using lifestyle to reduce risk. <i>Current Cardiovascular Risk Reports</i> , 2008, 2, 262-267.	2.0	0
150	Nonpharmacologic Management of Mixed Dyslipidemia Associated with Diabetes Mellitus and the Metabolic Syndrome: A Review of the Evidence. <i>American Journal of Cardiology</i> , 2008, 102, 14L-18L.	1.6	8
151	AJC Editor's Consensus: Psoriasis and Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2008, 102, 1631-1643.	1.6	148
152	Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly?. <i>Stroke</i> , 2007, 38, 441-450.	2.0	55
153	Metabolic syndrome management. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2059-2075.	1.8	10
154	Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus. <i>Circulation</i> , 2007, 115, 114-126.	1.6	634
155	Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update. <i>Circulation</i> , 2007, 115, 1481-1501.	1.6	600
156	Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1230-1250.	2.8	359
157	Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus. <i>Diabetes Care</i> , 2007, 30, 162-172.	8.6	577
158	Efficacy of Drug Therapy in the Secondary Prevention of Cardiovascular Disease and Stroke. <i>American Journal of Cardiology</i> , 2007, 99, S1-S35.	1.6	20
159	Management of Lipids in the Elderly. , 2007, , 369-387.		0
160	Drugs for Elevated LDL-Cholesterol. , 2007, , 528-539.		0
161	Clinical Confidence and the Three C's™: Caring, Communicating, and Competence. <i>American Journal of Medicine</i> , 2006, 119, 1-2.	1.5	1
162	Therapy and clinical trials. <i>Current Opinion in Lipidology</i> , 2006, 17, 199-201.	2.7	0

#	ARTICLE	IF	CITATIONS
163	Application of Recent Definitions of the Metabolic Syndrome to Survey Data From the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II). Journal of the Cardiometabolic Syndrome, 2006, 1, 295-300.	1.7	2
164	Antiatherosclerotic and Antithrombotic Effects of Omega-3 Fatty Acids. American Journal of Cardiology, 2006, 98, 39-49.	1.6	168
165	Identifying Patients for Aggressive Cholesterol Lowering: The Risk Curve Concept. American Journal of Cardiology, 2006, 98, 1405-1408.	1.6	43
166	Successful control of dyslipidemia in patients with metabolic syndrome: focus on lifestyle changes. Clinical Cornerstone, 2006, 8, S15-S20.	0.7	15
167	Familial hypercholesterolemia: a challenge of diagnosis and therapy.. Cleveland Clinic Journal of Medicine, 2006, 73, 57-64.	1.3	29
168	Obesity and Lifestyle Modification. Fundamental and Clinical Cardiology, 2006, , 63-78.	0.0	0
169	The Metabolic Syndrome in Patients With Chronic Obstructive Pulmonary Disease. Journal of Cardiopulmonary Rehabilitation and Prevention, 2005, 25, 233-234.	0.5	1
170	Approach to Treatment of the Patient with Metabolic Syndrome: Lifestyle Therapy. American Journal of Cardiology, 2005, 96, 15-21.	1.6	67
171	Recent National Cholesterol Education Program Adult Treatment Panel III Update: Adjustments and Options. American Journal of Cardiology, 2005, 96, 53-59.	1.6	208
172	Managing Abnormal Blood Lipids. Circulation, 2005, 112, 3184-3209.	1.6	199
173	Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation, 2004, 110, 227-239.	1.6	5,602
174	Stopping Statins. Circulation, 2004, 110, 2280-2282.	1.6	14
175	A Summary of Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1329-1330.	2.4	55
176	Long-term survival of childhood coronary artery disease in a patient severely affected with familial hypercholesterolemia. American Journal of Cardiology, 2004, 94, 699-700.	1.6	8
177	Evidence-based treatment of lipids in the elderly. Current Atherosclerosis Reports, 2004, 6, 388-397.	4.8	8
178	Focus on lifestyle change and the metabolic syndrome. Endocrinology and Metabolism Clinics of North America, 2004, 33, 493-508.	3.2	24
179	Treatment of metabolic syndrome. Expert Review of Cardiovascular Therapy, 2004, 2, 213-228.	1.5	67
180	Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Journal of the American College of Cardiology, 2004, 44, 720-732.	2.8	1,207

#	ARTICLE	IF	CITATIONS
181	Goals of Statin Therapy: Three Viewpoints. <i>Atherosclerosis Supplements</i> , 2004, 5, 107-114.	1.2	4
182	Therapy and clinical trials. <i>Current Opinion in Lipidology</i> , 2004, 15, 97-99.	2.7	0
183	Hyperlipidaemia and cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2004, 15, 707-709.	2.7	1
184	Effects of dietary modification to reduce vascular risks and treatment of obesity. <i>Cardiology Clinics</i> , 2003, 21, 415-433.	2.2	4
185	Commentary. <i>Clinica Chimica Acta</i> , 2003, 332, 21.	1.1	2
186	American Heart Association Guide for Improving Cardiovascular Health at the Community Level. <i>Circulation</i> , 2003, 107, 645-651.	1.6	197
187	Are Statins Indicated for the Primary Prevention of Coronary Heart Disease in Octogenarians? Protagonist Viewpoint. <i>The American Journal of Geriatric Cardiology</i> , 2003, 12, 351-354.	0.6	1
188	Atorvastatin Inhibits Hypercholesterolemia-Induced Cellular Proliferation and Bone Matrix Production in the Rabbit Aortic Valve. <i>Circulation</i> , 2002, 105, 2660-2665.	1.6	296
189	AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update. <i>Circulation</i> , 2002, 106, 388-391.	1.6	1,623
190	Therapeutic lifestyle change and adult treatment panel III: Evidence then and now. <i>Current Atherosclerosis Reports</i> , 2002, 4, 433-443.	4.8	23
191	Goals of statin therapy: Three viewpoints. <i>Current Atherosclerosis Reports</i> , 2002, 4, 26-33.	4.8	5
192	Current drug treatments for lipid management. <i>Managed Care</i> , 2002, 11, 4-9.	0.3	1
193	Approach to the Patient with Hyperlipidemia. , 2001, , 115-132.		0
194	Lowering low-density cholesterol with diet: the important role of functional foods as adjuncts. <i>Coronary Artery Disease</i> , 2001, 12, 547-552.	0.7	8
195	Hyperlipidaemia and cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2001, 12, 667-669.	2.7	1
196	The optimal dietary strategy to manage risk associated with various dyslipidemias. <i>Current Cardiology Reports</i> , 2001, 3, 391-400.	2.9	3
197	Hyperlipidaemia and cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2000, 11, 437-439.	2.7	0
198	The Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto miocardio (GISSI)-Prevenzione trial on fish oil and vitamin E supplementation in myocardial infarction survivors. <i>Current Cardiology Reports</i> , 2000, 2, 445-451.	2.9	33

#	ARTICLE	IF	CITATIONS
199	EFFECTS OF DIETARY MODIFICATION AND TREATMENT OF OBESITY. Medical Clinics of North America, 2000, 84, 95-122.	2.5	20
200	Hyperlipidaemia and cardiovascular disease. Current Opinion in Lipidology, 1999, 10, 479.	2.7	0
201	Month-to-month variability of lipids, lipoproteins, and apolipoproteins and the impact of acute infection in adolescents. Journal of Pediatrics, 1998, 133, 242-246.	1.8	48
202	Hyperlipidemia and cardiovascular disease. Current Opinion in Lipidology, 1998, 9, 279-281.	2.7	2
203	The clinical and economic significance of atherosclerosis. American Journal of Medicine, 1996, 101, 6S-9S.	1.5	28
204	Lipid management: Current diet and drug treatment options. American Journal of Medicine, 1996, 101, 40S-49S.	1.5	49
205	Dietary Guidelines for Healthy American Adults. Circulation, 1996, 94, 1795-1800.	1.6	376
206	Fish Consumption, Fish Oil, Lipids, and Coronary Heart Disease. Circulation, 1996, 94, 2337-2340.	1.6	139
207	Secondary causes of hyperlipidemia. Medical Clinics of North America, 1994, 78, 117-141.	2.5	155
208	Diet, blood cholesterol levels, and coronary heart disease. Coronary Artery Disease, 1993, 4, 871-882.	0.7	8
209	Controlling cholesterol levels through diet. Postgraduate Medicine, 1988, 83, 229-242.	2.0	5
210	Secondary prevention and lipid lowering: Results and implications. American Heart Journal, 1985, 110, 1123-1127.	2.7	10
211	Putative atherogenic factors in patients with chronic renal failure. Progress in Cardiovascular Diseases, 1983, 26, 133-144.	3.1	64
212	National heart, lung, and blood institute type II coronary intervention study: Design, methods, and baseline characteristics. Contemporary Clinical Trials, 1982, 3, 91-111.	1.9	45
213	Reliability of assessing change with sequential coronary angiography. American Heart Journal, 1982, 104, 816-823.	2.7	38
214	Hemodialysis vs. peritoneal dialysis: Results of a 3-year prospective controlled study. Kidney International, 1981, 19, 341-348.	5.2	11
215	Electrophysiological Studies on Uremic Patients - Comparison of Peritoneal Dialysis and Hemodialysis. Clinical EEG (electroencephalography), 1980, 11, 72-82.	0.9	12
216	Metabolic Studies in Familial Hypercholesterolemia. Journal of Clinical Investigation, 1979, 64, 524-533.	8.2	200

#	ARTICLE	IF	CITATIONS
217	Cholesterol, colestipol and coronary heart disease. <i>Journal of Chronic Diseases</i> , 1978, 31, 1-3.	1.2	9
218	Genetics of the LDL receptor: Evidence that the mutations affecting binding and internalization are allelic. <i>Cell</i> , 1977, 12, 629-641.	28.9	164
219	Limitations of the Electrocardiographic Response to Exercise in Predicting Coronary-Artery Disease. <i>New England Journal of Medicine</i> , 1975, 293, 367-371.	27.0	309
220	Coronary Artery Disease in 116 Kindred with Familial Type II Hyperlipoproteinemia. <i>Circulation</i> , 1974, 49, 476-488.	1.6	444
221	The hyperlipidemias and coronary artery disease. <i>Disease-a-Month</i> , 1972, 18, 1-35.	1.1	3
222	Hyperlipoproteinemia and coronary heart disease. <i>Progress in Cardiovascular Diseases</i> , 1972, 14, 341-359.	3.1	25